Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria September 22, 2026 8:00 AM EDT
Company Participants
Sarah Cavanaugh – Senior Vice President of Corporate Affairs & Administration
Anthony S. Marucci – Founder, President, CEO & Director
Diane Young – Senior VP & Chief Medical Officer
Teri Lawver – SVP & Chief Commercial Officer
Margo Heath-Chiozzi – Senior Vice President of Regulatory Affairs
Tibor Keler – Founder, Chief Scientific Officer & Executive VP
Conference Call Participants
Nathanael Charoensook – Leerink Partners LLC, Research Division
Yaron Werber – TD Cowen, Research Division
Yatin Suneja – Guggenheim Securities, LLC, Research Division
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Samuel Slutsky – LifeSci Capital, LLC, Research Division
Judah Frommer – Morgan Stanley, Research Division
Derek Archila – Wells Fargo Securities, LLC, Research Division
Alexander Thompson – Stifel, Nicolaus & Company, Incorporated, Research Division
Omotolani Uthman – Goldman Sachs Group, Inc., Research Division
Gustave Diep – Barclays Bank PLC, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Celldex Therapeutics webcast. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your speaker today, Sarah Cavanaugh. Please go ahead.
Sarah Cavanaugh
Senior Vice President of Corporate Affairs & Administration
Thank you. Good morning, and thank you for joining us. We’re very excited to start our day discussing positive top line results from our 2 Phase III studies in chronic spontaneous urticaria, EMBARQ-CSU1 and EMBARQ-CSU2. In addition to being available on the webcast portal, the accompanying slides for this morning’s call are also on the Investor Relations page of our website in the Events section. Joining me on the call this morning are Anthony Marucci, Co-Founder, President and Chief Executive Officer; Dr. Tibor Keler, Co-Founder, Executive Vice President and Chief Scientific Officer; Dr. Diane Young, Senior Vice President and Chief Medical Officer; Teri Lawver, Senior Vice President and Chief Commercial
